Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Joe Krupa who wrote (6574)	1/25/2001 11:20:17 PM
From: Montana Wildhack	Respond to of 14101

Joe, Here is a link to Dave Poxon's terminology and his specialty - tech stocks. This explains his usage of TVAL etc for those not familiar. stockhouse.ca

To: Joe Krupa who wrote (6574)	1/26/2001 3:26:35 AM
From: Cal Gary	Read Replies (3) \| Respond to of 14101

Thanks Joe and Wolf for the links. Same sandbox but perhaps OT, but I was checking out Merck's NR on financial, 4Q and year end. merck.com Mr. Gilmartin said. VIOXX, a once-a-day medicine, is the only COX-2 indicated in the United States both for osteoarthritis and acute pain. Since its extraordinarily successful 1999 launch, VIOXX has become the world's fastest growing branded prescription arthritis medicine, and it is already Merck's second largest-selling medicine. In the United States, VIOXX now accounts for approximately 50 percent of new prescriptions in the COX-2 class, despite being second to market in this class in the United States. VIOXX achieved $2.2 billion in sales for the full year 2000, with $700 million in the fourth quarter. I'm trying to find further breakdown, sales by country, especially to see what VIOXX market penetration they have achieved in Europe in the past year. Sales outside of the United States accounted for 36% of the Company's human health sales for the year. Foreign exchange reduced the human health sales growth for the fourth quarter by four percentage points and by two percentage points for the year. I'm chewing down some crow, but I like the hammer today. I assum we should see a NR 'very shortly' that DMX will have made its first drawdown for at least $5mm from Acqua Wellington. Am I wrong to expect a NR for any closing of financing, even if its derrive from an equity line of credit? Earliest date for such NR maybe Feb 13, but more likely Feb 16. Anyone got a different opinion?? Using the the last 6 months quarterlies, DMX is using burning cash + cash used in working capital at a rate of roughly $3.5mm per quarter. Given cash on hand Nov 30 of $2.2mm, we are nearing the 2/3 mark of this current quarter. Cash at this time maybe close to $ -0.1mm = $2.2mm - ($3.5mm x 2/3). So DMX could be technically in the red by end of next week. Short term draws on bank lines should get DMX thru a couple of weeks. The preceding calc is JMHO and blurry eyed chicken (crow) scratches. I wonder how the employee are just about now, with the looming payroll next week? At least we have a solvency lawyer on the payroll, a skill that's no longer needed. <ggg>